Company Filing History:
Years Active: 2017-2025
Title: Innovations of Junling Zhao in Genetic Therapies
Introduction
Junling Zhao is a prominent inventor based in Columbia, MO (US), known for his significant contributions to the field of genetic therapies. He has been awarded four patents that focus on innovative treatments for muscular dystrophies and related conditions. His work aims to improve the lives of individuals suffering from these debilitating diseases.
Latest Patents
Zhao's latest patents include groundbreaking developments in dystrophin R16/R17 syntrophin PDZ fusion proteins. These synthetic nucleic acids encode mini and microdystrophin genes that comprise the membrane binding motifs or domains of the R10-R11-R12 region. The patents provide vectors, host cells, and methods for treating subjects suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or X-linked dilated cardiomyopathy (XLDC). Additionally, they address the amelioration of adverse effects associated with these conditions. Another significant patent involves modified dystrophin proteins, which also utilize synthetic nucleic acids to treat diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.
Career Highlights
Junling Zhao is affiliated with the University of Missouri, where he conducts research and develops innovative solutions in genetic therapies. His work has garnered attention for its potential to transform treatment options for patients with muscular dystrophies.
Collaborations
Zhao collaborates with notable colleagues, including Yi Lai and Yongping Yue, to advance research in his field. Their combined expertise contributes to the development of effective therapeutic strategies.
Conclusion
Junling Zhao's innovative work in genetic therapies highlights the potential for new treatments for muscular dystrophies. His patents represent significant advancements in the field, aiming to improve patient outcomes and quality of life.